CureVac N.V., a biotech company developing medicines based on messenger RNA (mRNA), announced that CureVac N.V. and an affiliate of GSK plc have entered into agreements with BioNTech SE and affiliate Pfizer, Inc. to resolve all pending patent litigation in the U.S. between the companies related to mRNA-based COVID-19 vaccines. The agreements also set a framework for resolving ongoing patent disputes outside the U.S. upon closing of BioNTech’s $1.25 billion acquisition of CureVac announced on Jun...